Use of...

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/506 (2006.01) A61P 25/28 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2580976

This invention relates to the use of 4-(4-methylpiperazin-l-ylmethyl)-N-[4- methyl-3-(4-pyridin-3-yl)pyrimidin-2- ylamino)phenyl]-benzamide, (also known as imatinib, gleevec, glivec, cgp57148b or 8TI571), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of c-fms associated diseases including; choriocarcinoma, malignant histiocytosis, embryonal carcinoma, endometrial carcinoma, brain microglial tumours, sarcoidosis, microglial cell involvement in normal and variant Creutzfeld- Jacob disease, and amyotrophic lateral sclerosis.

La présente invention décrit l~emploi du 4-(4-méthylpiperazin-1-ylméthyl)-N-[4-méthyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phényl]benzamide (aussi connu sous les appellations suivantes : imatinib, gleevec, glivec, cgp57148b ou STI571) ou d~un sel de qualité pharmaceutique de ce composé, dans la fabrication d~un médicament servant au traitement des maladies liées au c-fms. Lesdites maladies incluent : chorio-épithéliomes, histiocytose maligne, carcinomes embryonnaires, carcinomes de l~endomètre, tumeurs microgliales cérébrales, sarcoïdose, implication des cellules microgliales dans la maladie de Creutzfeld-Jacob ordinaire et dans sa variante, et sclérose latérale amyotrophique.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Use of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1704795

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.